Francesca Mandino

Jan 17, 2025 | medrxiv.org | Corey Horien |Francesca Mandino |Abigail Greene |Xilin Shen

James C. McPartland consults or has consulted with Customer Value Partners, Bridgebio, Determined Health, Apple, and BlackThorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Boards of Pastorus and Modern Clinics, and receives royalties from Guilford Press, Lambert, Oxford, and Springer. This work was supported by the National Institutes of Health (P50MH115716, T32GM007205 to CH and ASG, and TR001864 to ASG).

Jan 2, 2024 | nature.com | Hadi Vafaii |Francesca Mandino |Gabriel Desrosiers-Gregoire |David H. O’Connor |Xinxin Ge |Peter Herman | +3 more

AbstractLarge-scale functional networks have been characterized in both rodent and human brains, typically by analyzing fMRI-BOLD signals. However, the relationship between fMRI-BOLD and underlying neural activity is complex and incompletely understood, which poses challenges to interpreting network organization obtained using this technique. Additionally, most work has assumed a disjoint functional network organization (i.e., brain regions belong to one and only one network).

Dec 16, 2023 | biorxiv.org | Francesca Mandino |Xilin Shen |Gabriel Desrosiers-Gregoire |David O'Connor

AbstractAmyloid accumulation in Alzheimer's disease (AD) is associated with synaptic damage and altered connectivity in brain networks. While measures of amyloid accumulation and biochemical changes in mouse models have utility for translational studies of certain therapeutics, preclinical analysis of altered brain connectivity using clinically relevant fMRI measures has not been well developed for agents intended to improve neural networks.